Benzolactam compounds as protein kinase inhibitors
US11939321B2 · kind B2 · utility
0Cited by
4References
28Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 7, 2021 |
| Grant date | Mar 26, 2024 |
| Priority date | — |
| Expiry date | Apr 7, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D513/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a compound of formula (0): The compounds are inhibitors of ERK1/2 kinases and will be useful in the treatment of ERK1/2-mediated conditions. The compounds are therefore useful in therapy, in particular in the treatment of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.